Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 726.5 DKK 4.23% Market Closed
Market Cap: 51.5B DKK
Have any thoughts about
Zealand Pharma A/S?
Write Note

Zealand Pharma A/S
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zealand Pharma A/S
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Zealand Pharma A/S
CSE:ZEAL
Effect of Foreign Exchange Rates
-kr4.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Effect of Foreign Exchange Rates
kr17m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
22%
Ascendis Pharma A/S
NASDAQ:ASND
Effect of Foreign Exchange Rates
€4.7m
CAGR 3-Years
N/A
CAGR 5-Years
30%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Effect of Foreign Exchange Rates
kr2.2m
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
N/A
F
Fluoguide AS
STO:FLUO
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Effect of Foreign Exchange Rates
-kr56k
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zealand Pharma A/S
Glance View

Market Cap
51.3B DKK
Industry
Biotechnology

Zealand Pharma A/S is a dynamic biotechnology company based in Denmark, on a mission to create innovative peptide-based therapeutics that address unmet medical needs, particularly in the fields of diabetes, obesity, and gastrointestinal disorders. Founded in 1999, Zealand's commitment to research excellence has positioned it at the forefront of peptide drug discovery and development. Its proprietary pipeline includes promising candidates such as dasiglucagon, an ultra-rapid treatment for diabetes, and ezotic for obesity management, illustrating the company's focus on high-impact therapeutic solutions that aim to improve the quality of life for patients worldwide. As an investor, understanding Zealand's strategic partnerships and collaborations with major pharmaceutical organizations underscores its ability to leverage expertise and resources, thereby accelerating the development of its product offerings. With a strong foundation built on scientific innovation, Zealand Pharma has garnered significant attention from the investment community, reflecting its robust growth potential. The company’s publicly traded status on NASDAQ Copenhagen allows investors to participate in its journey as it aims for regulatory approvals and commercialization of its lead candidates. Zealand's agile approach to the ever-evolving landscape of biotechnology, combined with a commitment to sustainable practices, positions it as a forward-thinking player in the industry. Thus, for investors, Zealand Pharma presents a compelling opportunity within the healthcare sector, where advancements in biopharma are increasingly critical in addressing global health challenges.

ZEAL Intrinsic Value
174.29 DKK
Overvaluation 76%
Intrinsic Value
Price

See Also

What is Zealand Pharma A/S's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
-4.3m DKK

Based on the financial report for Sep 30, 2024, Zealand Pharma A/S's Effect of Foreign Exchange Rates amounts to -4.3m DKK.

What is Zealand Pharma A/S's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 1Y
80%

Over the last year, the Effect of Foreign Exchange Rates growth was 80%.

Back to Top